Neglected giant benign phyllode tumor of the breast

Marc-Antoine Benderra¹, Clement Ferrier², David Buob³, Joseph Gligorov^{4

5}, Khaldoun Kerrou^{5

6}

Affiliations

¹ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Medical Oncology, Paris, France. marc-antoine.benderra@aphp.fr.
² Sorbonne University, APHP, Tenon Hospital, Department of Gynaecology and Obstetrics, Paris, France.
³ Sorbonne University, APHP, Tenon Hospital, Department of Pathology, Paris, France.
⁴ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Medical Oncology, Paris, France.
⁵ Team Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Inserm UMR_S 938, Paris, France.
⁶ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Nuclear Medicine and PET Center, Paris, France.

Marc-Antoine Benderra et al. Eur J Nucl Med Mol Imaging. 2022 Sep.

. 2022 Sep;49(11):3954-3955.

doi: 10.1007/s00259-022-05840-7. Epub 2022 May 18.

Marc-Antoine Benderra¹, Clement Ferrier², David Buob³, Joseph Gligorov^{4

5}, Khaldoun Kerrou^{5

6}

¹ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Medical Oncology, Paris, France. marc-antoine.benderra@aphp.fr.
² Sorbonne University, APHP, Tenon Hospital, Department of Gynaecology and Obstetrics, Paris, France.
³ Sorbonne University, APHP, Tenon Hospital, Department of Pathology, Paris, France.
⁴ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Medical Oncology, Paris, France.
⁵ Team Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Inserm UMR_S 938, Paris, France.
⁶ Institut Universitaire de Cancérologie, Sorbonne University, AP-HP, Tenon Hospital, Department of Nuclear Medicine and PET Center, Paris, France.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

1. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 1 août. 2019;37(22):1868–75. doi: 10.1200/JCO.19.00066. - DOI - PMC - PubMed